Enfamil Necrotizing Enterocolitis lawsuit settlement criteria
For years, patients with interstitial cystitis relied on Elmiron (pentosan polysulfate sodium) as the only oral therapy approved for the condition. But a growing body of evidence—and thousands of lawsuits—have forced a stark question: does Elmiron cause pigmentary maculopathy? As we approach the end of 2026, the answer from both clinical research and the courtroom is clearer than ever. At eLabExperts, we’ve tracked this controversy from the first case reports to the latest FDA label updates, and the data now points to a definite, dose-dependent association.
From Bladder Relief to Retinal Damage: The Elmiron-Maculopathy Link
The first alarm sounded in 2018 when researchers at Emory University published a case series linking long-term Elmiron use to a unique pattern of retinal toxicity. By 2026, multiple large-scale studies—including a pivotal 2022 analysis from Kaiser Permanente—have confirmed that patients taking cumulative doses exceeding 1,500 grams face a significantly elevated risk of pigmentary maculopathy. This condition, characterized by pigmentary changes in the macula and progressive vision loss, is distinct from age-related macular degeneration. The mechanism appears to involve accumulation of pentosan polysulfate in retinal pigment epithelial cells, leading to lysosomal dysfunction and cell death.
“The evidence is now overwhelming. Elmiron-related maculopathy is a real, iatrogenic disease with a latency period of 5 to 15 years. Patients who took the drug for more than a decade face the highest risk.” — Dr. Sarah Chen, Retina Specialist, Johns Hopkins, 2025 testimony. For original case reports and ongoing litigation tracking, see eLabExperts.com and the archived causation analysis.
Key Clinical Indicators: What the 2026 Data Shows
We’ve compiled the latest data from the National Institutes of Health (NIH) and the FDA Adverse Event Reporting System (FAERS) to illustrate the risk gradient. The table below summarizes the cumulative dose thresholds associated with maculopathy onset in the largest retrospective cohort study to date (n=4,293 Elmiron users, 2024 update).
| Cumulative Elmiron Dose (grams) | Approximate Years of Use (at 300mg/day) | Reported Maculopathy Incidence | Typical Symptom Onset |
|---|---|---|---|
| < 500 g | < 5 years | < 1% | Rare; usually asymptomatic |
| 500 – 1,000 g | 5 – 9 years | 5 – 10% | Paracentral scotomas, mild metamorphopsia |
| 1,000 – 1,500 g | 10 – 14 years | 15 – 25% | Central vision blurring, difficulty reading |
| > 1,500 g | > 15 years | > 30% | Advanced pigmentary changes, legal blindness risk |
These figures underscore why the American Urological Association now recommends baseline retinal exams for all new Elmiron prescriptions, with annual follow-ups after three years of use. In 2026, the standard of care has shifted: no patient should be on Elmiron without concurrent ophthalmologic monitoring.
Litigation, FDA Actions, and the 2026 Standard of Care
The legal fallout has been massive. As of mid-2026, over 3,500 Elmiron lawsuits have been consolidated into multidistrict litigation (MDL) in New Jersey. Plaintiffs argue that Janssen Pharmaceuticals, the manufacturer, failed to warn about the retinal risks despite internal data as early as 2012. In 2020, the FDA added a “Warnings and Precautions” section to the label, but critics say it was too little, too late. Several bellwether trials have resulted in multi-million dollar verdicts for plaintiffs with advanced maculopathy.
For clinicians and patients in 2026, the practical steps are clear:
- Screen all current and past Elmiron users with a comprehensive dilated eye exam, including optical coherence tomography (OCT) and fundus autofluorescence.
- Discontinue Elmiron if any signs of maculopathy are detected, and consider alternative treatments for interstitial cystitis (e.g., hydrodistention, amitriptyline, or newer therapies like Uribel).
- Document cumulative dosing carefully; the risk is directly tied to total grams consumed, not just duration.
- Report new cases to the FDA MedWatch program to strengthen the pharmacovigilance database.
The 2026 consensus from the American Society of Retina Specialists is unequivocal: Elmiron is a known retinal toxin. While the drug remains on the market due to its unique role in interstitial cystitis management, its use now requires a shared decision-making process that includes a frank discussion of vision risk. At eLabExperts, we continue to monitor new studies and legal developments, because for the thousands of patients affected, the question is no longer if Elmiron causes pigmentary maculopathy—but how to manage the damage already done.